Seer Inc
Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab fo… Read more
Seer Inc (SEER) - Net Assets
Latest net assets as of September 2025: $271.81 Million USD
Based on the latest financial reports, Seer Inc (SEER) has net assets worth $271.81 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($308.61 Million) and total liabilities ($36.79 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $271.81 Million |
| % of Total Assets | 88.08% |
| Annual Growth Rate | 48.95% |
| 5-Year Change | -24.11% |
| 10-Year Change | N/A |
| Growth Volatility | 152.32 |
Seer Inc - Net Assets Trend (2018–2024)
This chart illustrates how Seer Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Seer Inc (2018–2024)
The table below shows the annual net assets of Seer Inc from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $327.57 Million | -17.47% |
| 2023-12-31 | $396.90 Million | -11.21% |
| 2022-12-31 | $446.99 Million | -11.12% |
| 2021-12-31 | $502.92 Million | +16.52% |
| 2020-12-31 | $431.61 Million | +392.26% |
| 2019-12-31 | $87.68 Million | +192.51% |
| 2018-12-31 | $29.98 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Seer Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 38582400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | 0.00% |
| Other Comprehensive Income | $136.00K | 0.04% |
| Other Components | $719.80 Million | 219.74% |
| Total Equity | $327.57 Million | 100.00% |
Seer Inc Competitors by Market Cap
The table below lists competitors of Seer Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BIEN SPAREB.AS NK 34375
F:JX0
|
$71.13 Million |
|
Brighten Optix Corporation
TWO:6747
|
$71.13 Million |
|
Samart Corporation Public Company Limited
BK:SAMART
|
$71.17 Million |
|
Embassy Bancorp Inc
OTCQX:EMYB
|
$71.17 Million |
|
Soosan Industries Co. Ltd.
KO:126720
|
$71.09 Million |
|
Atland S.A.
PA:ATLD
|
$71.09 Million |
|
Ratchthani Leasing Public Company Limited
BK:THANI
|
$71.07 Million |
|
KISCO Corp
KO:104700
|
$71.06 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Seer Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 396,904,000 to 327,569,000, a change of -69,335,000 (-17.5%).
- Net loss of 86,599,000 reduced equity.
- Share repurchases of 11,816,000 reduced equity.
- Other comprehensive income increased equity by 328,000.
- Other factors increased equity by 28,752,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-86.60 Million | -26.44% |
| Share Repurchases | $11.82 Million | -3.61% |
| Other Comprehensive Income | $328.00K | +0.1% |
| Other Changes | $28.75 Million | +8.78% |
| Total Change | $- | -17.47% |
Book Value vs Market Value Analysis
This analysis compares Seer Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.34x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.27x to 0.34x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $1.40 | $1.78 | x |
| 2019-12-31 | $1.44 | $1.78 | x |
| 2020-12-31 | $7.09 | $1.78 | x |
| 2021-12-31 | $8.26 | $1.78 | x |
| 2022-12-31 | $7.16 | $1.78 | x |
| 2023-12-31 | $6.22 | $1.78 | x |
| 2024-12-31 | $5.25 | $1.78 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Seer Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -26.44%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -620.91%
- • Asset Turnover: 0.04x
- • Equity Multiplier: 1.12x
- Recent ROE (-26.44%) is below the historical average (-18.58%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -21.04% | 0.00% | 0.00x | 1.12x | $-9.30 Million |
| 2019 | -18.29% | -13825.86% | 0.00x | 1.06x | $-24.81 Million |
| 2020 | -7.59% | -4996.19% | 0.00x | 1.02x | $-75.94 Million |
| 2021 | -14.15% | -1113.06% | 0.01x | 1.07x | $-121.46 Million |
| 2022 | -20.80% | -633.07% | 0.03x | 1.09x | $-137.67 Million |
| 2023 | -21.74% | -568.28% | 0.03x | 1.10x | $-125.97 Million |
| 2024 | -26.44% | -620.91% | 0.04x | 1.12x | $-119.36 Million |
Industry Comparison
This section compares Seer Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Seer Inc (SEER) | $271.81 Million | -21.04% | 0.14x | $71.12 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |